62176-31-2Relevant articles and documents
Metal-free Synthesis of Spiro-2,2′-benzo[b]furan-3,3′-ones via PhI(OAc)2-Mediated Cascade Spirocyclization
Xing, Qingyu,Liang, Huiyuan,Bao, Mingmai,Li, Xuemin,Zhang, Jingran,Bi, Tianhao,Zhang, Yilin,Xu, Jun,Du, Yunfei,Zhao, Kang
supporting information, p. 4669 - 4673 (2019/09/17)
Treating the benzyl protected 3-hydroxy-1,3-bis(2-hydroxyphenyl)prop-2-en-1-ones solely with PhI(OAc)2 (PIDA) in DCE at room temperature readily furnished the seldom studied spiro-2,2′-benzo[b]furan-3,3′-ones in satisfactory to excellent yields. The hypervalent iodine reagent enables the metal-free cascade spirocyclization resulting in the dual oxidative C?O bond formation. (Figure presented.).
Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors
Ding, Xiao,Dai, Xuedong,Long, Kai,Peng, Cheng,Andreotti, Daniele,Bamborough, Paul,Eatherton, Andrew J.,Edge, Colin,Jandu, Karamjit S.,Nichols, Paula L.,Philps, Oliver J.,Stasi, Luigi Piero,Wan, Zehong,Xiang, Jia-Ning,Dong, Kelly,Dossang, Pamela,Ho, Ming-Hsun,Li, Yi,Mensah, Lucy,Guan, Xiaoming,Reith, Alastair D.,Ren, Feng
supporting information, p. 4034 - 4038 (2017/08/23)
Leucine-rich repeat kinase 2 (LRRK2) has been suggested as a potential therapeutic target for Parkinson's disease. Herein we report the discovery of 5-substituent-N-arylbenzamide derivatives as novel LRRK2 inhibitors. Extensive SAR study led to the discovery of compounds 8e, which demonstrated potent LRRK2 inhibition activity, high selectivity across the kinome, good brain exposure, and high oral bioavailability.